Target intelligence / Profile preview

Uncharacterized protein KIAA1671 (KIAA1671)

Target
KIAA1671
Molecular classification
Other (uncharacterized, predicted to be a largely disordered protein), Actin-binding protein (tentative; shows strong localization to F-actin networks but not confirmed as a classical actin-binding protein)[2][3]
01

Overview

KIAA1671 is a large (∼196 kDa) and largely disordered protein found in humans, initially identified in large-scale genomic and proteomic studies. Recent spatial proteomics and cell imaging work reveal that it is a resident protein of the brush border actin cytoskeleton in polarised intestinal epithelial cells: it localizes specifically to the subapical terminal web at the base of microvilli, and targets F-actin–rich networks in both polarized and nonpolarized cell types. The protein is implicated in the initiation and formation of microvilli, acting in close association with EPS8 and potentially other assembly factors during early stages of microvillar growth. It associates dynamically with F-actin-rich puncta, suggesting a possible role in actin polymerization, though it lacks canonical actin-binding motifs. Bioinformatics and proteomic data indicate potential interaction with capping protein (CAPZA2) and possible regulation of filament growth. KIAA1671 remains largely uncharacterized outside these recent cellular studies and is not considered a classical drug target, receptor, or enzyme to date[2][3].

Other names
KIAA1671CTA-221G9.5Uncharacterized protein KIAA1671
02

Mechanism of action

None established for drugs targeting this molecule

03

Biological functions

Microvillus biogenesis (initiation and base formation of microvilli in polarized epithelial cells)[2][3]Actin cytoskeleton organization (colocalizes and migrates with dynamic F-actin networks)[2][3]Possible regulation of capping protein (CAPZA2) activity (based on sequence similarity and interaction studies)[2][3]Other (general cytoskeletal remodeling – still largely speculative)
04

Disease associations

Other (no clear disease associations have been established as of now)
05

Safety considerations

None known (not used as a therapeutic target, so no specific safety concerns are described)
06

Interacting drugs

None known (no drugs reported to interact with KIAA1671)[2][3]
07

Biomarkers

None established for patient selection or efficacy monitoring

Beyond the preview

Go deeper on Uncharacterized protein KIAA1671 (KIAA1671).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uncharacterized protein KIAA1671 (KIAA1671).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call